MNMohammed T. Numan

Mohammed T. Numan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohammed T. Numan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Anand Gourishankar

    Children's National Hospital

    2 shared publications
  • Ian Butler

    University of Texas

    2 shared publications
  • Ian J. Butler

    Division of Child and Adolescent Neurology, Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, USA

    2 shared publications
  • Jeremy E. Lankford

    Division of Child and Adolescent Neurology, Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, USA

    2 shared publications
  • Rawan Alnajjar

    University of Texas Medical Branch

    2 shared publications
  • Ankur Kamdar

    Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center , Houston, Texas

    1 shared publication

Latest Publications

  • Open Access

    Postapproval Study Outcomes of Muscular Ventricular Septal Defect Closure With the Amplatzer Muscular VSD Occluder

    by Athar M. Qureshi, Henri Justino, Carl Owada, Mohammed Numan, Makram Ebeid, Thomas J. Forbes, David Nykanen, Daisuke Kobayashi, Jillian Kolles, Dan Gutfinger, et al.

    BACKGROUND: The Amplatzer Muscular Ventricular Septal Defect (VSD) Occluder (Abbott Structural Heart, Plymouth, MN) was approved by the US Food and Drug Administration in 2007. As a condition of approval, a postapproval study was required to further evaluate its safety and effectiveness. This study reports the clinical outcomes from the postapproval study over 5 years of follow-up. METHODS: Patients with complex congenital muscular VSDs at high risk for surgical closure were enrolled between May 2008 and February 2020 in the United States and Canada. The primary effectiveness end points were technical implant success, acute procedure shunt-closure success, and 1-year shunt-closure success. The primary safety end point was the proportion of patients with any serious adverse event within 12 months of the procedure. RESULTS: A total of 92 patients (median age, 2 years; 50 females) were enrolled in the study. Technical implant success was achieved in 93.8% of patients, and acute shunt-closure success was achieved in 78.0%. Successful shunt closure at 1-year was 94.4% and increased to >98% between 2 and 5 years. Within 12 months of the procedure, all-cause serious adverse events occurred in 47 of the 90 (52.2%) patients which included 7 device-related and 23 procedure-related serious adverse events. Between 1 and 5 years, there was 1 additional device- and procedure-related serious adverse event. CONCLUSIONS: This postapproval study demonstrates that transcatheter muscular VSD closure with the Amplatzer Muscular VSD Occluder is a safe and effective therapy for the treatment of complex congenital muscular VSDs in patients who are at high-risk for surgical closure. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00647387.

  • Cardiac Electrophysiology

    by Luis A. Ochoa, Mohammed T. Numan

  • Arterial Baroreceptor Physiology: Differences Between Normal Subjects and Pediatric Patients with Postural Tachycardia and Neurocardiogenic Syncope

    by Mohammad S. Alnoor, Holly K. Varner, Ian J. Butler, Jeremy E. Lankford, Liang Zhu, Mohammed T. Numan

    The arterial baroreceptor reflex in children and adolescents has not been well studied in the current literature with a lack of agreed upon normal values, particularly in postural orthostatic tachycardia syndrome (POTS) or neurocardiogenic syncope (NCS). We used the sequence method and head-up tilt test (HUTT) to evaluate baroreceptor function in 3 phases: baseline supine position for 10 min, head-up position at 70° for 30 min or until syncope, and post-tilt supine reposition for 10 min. We measured the number of baroreceptor events, baroreceptor effectiveness index (BEI), and the magnitude of sensitivity of the events at each phase of HUTT. We studied 198 individuals (49 normal subjects, 67 POTS, 82 NCS) with age ranges from 8 to 21 years. The data show a statistically significant decrease in slope and BEI in patients with POTS and NCS during the head-up phase, with an increase in activity in the lag 1 and 2 portions of all phases in patients with POTS. This study provides terminology to describe baroreceptor function and identifies the slope and BEI portions of the baroreceptor reflex as the most useful objective measures to differentiate pediatric patients with POTS and NCS from normal subjects.


  • Open Access

    Demographic and clinical features of pediatric patients with orthostatic intolerance and an abnormal head-up tilt table test; A retrospective descriptive study

    by Anand Gourishankar, Mathew D. Belton, S. Shahrukh Hashmi, Ian J. Butler, Jeremy E. Lankford, Mohammed T. Numan


  • Open Access

    Autologous Adipose Stem Cell Therapy for Autonomic Nervous System Dysfunction in Two Young Patients

    by Mohammed T. Numan, Ankur Kamdar, Jane Young, Ian. J. Butler

    Postural orthostatic tachycardia syndrome and neurocardiogenic syncope are clinical manifestations of autonomic nervous system dysfunction (dysautonomia) that can lead to impaired daily functions. We report two young patients presenting with dysautonomia and autoimmune disease who both received autologous adipose stem cells (ASCs) infusions. This report is the first description of ASCs therapy for patients with combined dysautonomia and autoimmune disease. Case 1: A 21-year-old female presented at 12 years of age with escalating severe dysautonomia with weight loss and gastrointestinal symptoms. She had elevated autoantibodies and cytokines and received multiple immune modulation therapies. Her dysautonomia was treated by volume expanders, vasoconstrictors, and beta blockers with mild improvement. She received ASCs about 2 years before this report with dramatic improvement in her dysautonomia and autoimmune symptoms with a 10 kg weight gain. Case 2: A 7-year-old boy presented at 2 years of age with polyarthritis. At 5 years of age, he manifested orthostatic intolerance. He received immune modulatory therapies with mild improvement. He received ASCs and showed marked improvement of his dysautonomia and immune symptoms. Dysautonomia symptoms of these two patients improved significantly after modulation of autoimmune components by ASC therapy. Favorable clinical responses of these two cases warrant further case–control studies.


  • Dominant Transmission Observed in Adolescents and Families With Orthostatic Intolerance

    by Jennifer E. Posey, Rebecca Martinez, Jeremy E. Lankford, James R. Lupski, Mohammed T. Numan, Ian J. Butler


  • Medium to long-term echo follow-up after ventricular septal defect device closure

    by Muhammed Riyas K Rahmath, Mohammed Numan, Muhammad Dilawar

    Objective: We aimed to assess the medium to long-term results of echocardiographic follow-up of perimembranous and muscular ventricular septal defect closure with various Amplatzer devices. Methods: We successfully closed ventricular septal defects percutaneously in 45/49 patients. There were 35 perimembranous and 10 muscular ventricular septal defects. The median age and weight was 8.50 years (range 2–36.70 years) and 24 kg (range 10–106 kg), respectively. The median size of the ventricular septal defect was 7 mm (range 3–14 mm) on transthoracic echocardiography, 6 mm (range 4–15 mm) on transesophageal echocardiography, and 6 mm (range 3–14 mm) on left ventricular angiography. The median pulmonary-to-systemic blood flow ratio was 1.40 (range 1.0–3.0). Results: In the 49 attempted cases, the procedure was successful in 45, with a success rate of 91.84%. At a mean follow-up of 54.50 months, echocardiography showed complete closure in 41 (91%) patients and 4 (9%) had a tiny (1–2 mm) residual defect. New-onset aortic regurgitation was seen in 6 (13.3%) patients at 54.50 months, but it was mild in nature. Tricuspid valve regurgitation was observed in 13 (29%) patients at 54.50 follow-up, of whom 10 (22%) had mild and 3 (7%) had moderate regurgitation. Conclusion: Transcatheter closure of perimembranous and muscular ventricular septal defects is effective, however, these patients need to be followed up regularly to detect device-related problems, specifically, aortic and tricuspid valve regurgitation.


  • Ibn Al Nafis: His Seminal Contributions to Cardiology

    by Mohammed T. Numan

    Ibn Al Nafis, born 1213, was the first to discover the “circulation lesser” and describe the blood flow from the right ventricle to the lungs then back to the left ventricle 300 years before William Harvey. He bravely rejected the theory of Galen (130–200 AD) and Avicenna (980–1037 AD) which stated that the blood from the right ventricle passes through “invisible” holes in the ventricular septum to the left ventricle. Also was the first to note that the nourishment of the heart muscle is coming from the coronary arteries rather than from the inside of the ventricular cavity as described by earlier scholars.


  • Cardiac Asystole During Head Up Tilt (HUTT) in Children and Adolescents: Is this Benign Physiology?

    by Mohammed Numan, Rawan Alnajjar, Jeremy Lankford, Anand Gourishankar, Ian Butler

    Cardiac asystole during HUTT has been described by some investigators as a benign finding with no major sequelae. Our aim in this study is to correlate the severity of clinical symptoms and physiologic findings prior and during the asystole occurrence. This is a retrospective study review of 536 patients who underwent HUTT for dysautonomia symptoms for the last 3 years. HUTT in our institution consists of 10 min in supine, 30 min of head up at 70°, and recline to supine for 10 min. Physiologic parameters recorded include continuous heart rate, BP, cardiac stroke volume, brain blood flow by near-infra red spectroscopy, sympathetic and parasympathetic tones. Patients' complaints and signs during HUTT were recorded. Follow-up was conducted up to 34 months. Cardiac asystole was defined as the absence of ventricular activity for ≥3 s with cessation of BP signal for the same period on the monitor. Of the 536 patients studied, 25 patients developed cardiac asystole (4.7%). The asystolic group age was 15.1 + 3.8 years and weighed 56.7 + 21 kg. All the patients fainted and were not able to complete the test with average head up time of 13.8 + 7.1 min. The cardiac asystole duration was 9.2 + 5.8 s. Sixteen patients developed convulsions during the asystole. There was sudden intense vagal tone prior to and during the asystole. Brain perfusion was significantly decreased in all the patients after head up and sharply dropped by 20-35% in patients who developed convulsions. All patients completely recovered their consciousness after reposition to supine. During recovery, there was overshoot of the brain perfusion above the baseline for several minutes and the HR returned to baseline. Follow-up of these patients: only one patient had a single lead pacemaker, otherwise the 24 patients had no cardiac pacing and were treated by medical therapy. During mean follow-up of 19 + 10 months, five patients developed syncope which resolved after optimizing medical therapy. Cardiac asystole due to neurocardiogenic syncope and dysautonomia has high association with brain anoxia that can lead to convulsions. Such patients require intense medical therapy and close observation with possible intervention by cardiac pacing if prolonged asystole occurs. There is a concern of consequence future brain function.